Monday, August 16, 2021

Helius Medical Technologies (HSDT)(HSM:CA)
Reports 2Q21 Results; U.S. Efforts Ongoing

Helius Medical Technologies is a neurotech company focused on neurological wellness. The Company’s purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company’s first commercial product is the Portable Neuromodulation Stimulator (PoNSTM). For more information, visit www.heliusmedical.com.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

2Q21 Results. Canadian COVID related restrictions continue to impact Helius operating results. Helius reported 2Q revenue of $71,000 down from $84,000 in 1Q21. Net loss for the quarter including $2.6 million of stock-based compensation expense was $6.0 million, or $2.58 per share, compared to a net loss of $3.6 million, or $2.90 per share last year. We had forecast revenue of $90,000 and a net loss of $3.6 million, or $1.53 per share.


U.S. Commercialization Efforts Ongoing. Helius continues to develop a plan for U.S. commercialization of the PoNS Treatment. The Company recently hired a new VP of Sales & Marketing for North America, Fred Fantazzia, an expert in developing the market for new neuromodulation technologies. State approvals rose to 43 from 24 at the end of 1Q21. The Company has refined its initial target market to 10 …

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision.